The charts on this page feature a breakdown of the total annual pay for the top executives at AEGERION PHARMACEUTICALS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. AEGERION PHARMACEUTICALS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. AEGERION PHARMACEUTICALS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Sandford D. Smith
(former interim Chief Executive Officer), Director
Total Cash $411,705 Equity $661,829 Other $70,230 Total Compensation $1,143,764
Mark Sumeray
(former Chief Medical Officer)
Total Cash $405,000 Equity $1,313,164 Other $56,965 Total Compensation $1,775,129
Marc Beer
(former Chief Executive Officer)
Total Cash $370,417 Equity $2,906,057 Other $344,398 Total Compensation $3,620,872
Mark Fitzpatrick
(former Chief Financial Officer)
Total Cash $159,521 Equity $1,043,955 Other $9,171 Total Compensation $1,212,647
Martha Carter
(Chief Regulatory Officer)
Total Cash $340,000 Equity $1,287,734 Other $7,800 Total Compensation $1,635,534
Mary Weger
(former Chief Performance Officer)
Total Cash $345,000 Equity $1,039,327 Other $119,907 Total Compensation $1,504,234
David Aubuchon
(former acting Chief Financial Officer)
Total Cash $242,603 Equity $634,696 Other $5,763 Total Compensation $883,062
Gregory Perry
(Chief Financial & Administration Officer)
Total Cash $274,583 Equity $2,707,048 Other $38,705 Total Compensation $3,020,336

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.